Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company whose news flow centers on the development of CRISPR-based therapies. Company announcements frequently highlight progress in its in vivo programs, including nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Investors following NTLA news can see updates on clinical trial data, regulatory interactions and platform developments that shape the company’s pipeline.
Recent Intellia press releases and SEC-furnished materials describe longer-term Phase 1 and Phase 1/2 data for nex-z and lonvo-z, pooled analyses of patient outcomes, and details from global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO. News items also cover events such as temporary pauses in patient dosing, FDA clinical holds on Phase 3 nex-z trials, and subsequent company plans to work with regulators. These disclosures provide insight into both the potential and the risks associated with Intellia’s CRISPR-based candidates.
Beyond clinical results, NTLA news includes quarterly financial updates, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor presentations at major healthcare conferences. Together, these items give a view into Intellia’s operational progress, capital position and strategic priorities as it advances gene editing therapies for serious diseases like ATTR amyloidosis and HAE.
This news page aggregates Intellia’s latest press releases and related market-moving information in one place, allowing readers to review clinical milestones, regulatory developments and corporate updates linked to the NTLA stock.
Intellia Therapeutics (NASDAQ: NTLA) outlines its strategic priorities for 2023-2024, emphasizing late-stage development of CRISPR-based therapies NTLA-2001 and NTLA-2002. Key milestones include submitting IND applications for these treatments and initiating pivotal global studies by the end of 2023. The company ended 2022 with approximately $1.3 billion in cash, indicating a strong financial position. Intellia aims to advance novel gene editing technologies and maintain its leadership in genome editing through high-impact opportunities.
Intellia Therapeutics (NASDAQ:NTLA) has priced a public offering of 6,550,219 shares at $45.80 each, aiming to raise approximately $300 million. The underwriter, Goldman Sachs, has a 30-day option for an additional 982,532 shares. The offering is set to close around December 2, 2022, based on standard conditions. The shares are offered under an existing SEC registration statement. Intellia specializes in CRISPR-based genome editing therapies, focusing on potential cures for diseases through innovative therapeutic approaches.
Intellia Therapeutics (NASDAQ: NTLA) announced a public offering of $250 million in common stock, with a potential additional 15% option for underwriters. Goldman Sachs & Co. LLC is the sole underwriter. The offering is subject to market conditions and follows an effective shelf registration with the SEC. A preliminary prospectus will be available soon. The funds raised are intended to enhance Intellia's development of CRISPR-based therapies. However, there is no guarantee on the offering's completion or terms.
Intellia Therapeutics has released promising interim data from its Phase 1/2 clinical trial of NTLA-2002, a CRISPR-based therapy for hereditary angioedema (HAE). Results show robust reductions in plasma kallikrein levels and HAE attack rates across all tested doses. Notably, patients in the 25 mg and 75 mg cohorts remain attack-free through the latest follow-up, with intervals lasting between 5.5 to 10.6 months. The treatment was well-tolerated, with no serious adverse effects reported. An investor event discussing these findings is scheduled for November 14, 2022.
Intellia Therapeutics (NASDAQ:NTLA) has presented interim results from its Phase 1 trial of NTLA-2001, a CRISPR-based treatment for ATTR amyloidosis with cardiomyopathy. Results showed a remarkable 90% mean serum TTR reduction following a single dose, sustained for four to six months. NTLA-2001 was generally well-tolerated, with minimal adverse reactions. This study marks a significant step in exploring the potential of NTLA-2001 to permanently inactivate the TTR gene, offering a promising future for patients with this life-threatening condition.
Intellia Therapeutics (NTLA) reported significant interim results from its clinical trials for NTLA-2001 and NTLA-2002 in the third quarter of 2022. NTLA-2001 showed mean serum transthyretin protein reductions of 93% and 92% at doses of 0.7 mg/kg and 1.0 mg/kg, respectively. The firm has strong cash reserves of $848.7 million and expects to initiate Phase 2 of NTLA-2002 by early 2023. Collaboration revenue increased to $13.3 million, while R&D expenses rose to $96.7 million. The net loss was reported at $113.2 million, indicating an increase compared to the previous year.
Intellia Therapeutics (NASDAQ: NTLA) announced new interim clinical data from its Phase 1/2 study of NTLA-2002, showcasing safety, kallikrein reduction, and attack rate information. This investigational CRISPR/Cas9 therapy aims to prevent angioedema attacks in hereditary angioedema (HAE) patients. Key presentation details include:
- Date: Nov 12, 2022
- Presenter: Dr. Hilary Longhurst
A live webcast to discuss the data will be held on Nov 14, 2022. NTLA-2002 represents a novel approach to a rare genetic disorder affecting 1 in 50,000 people.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present its Q3 2022 financial results and operational highlights on a conference call scheduled for November 3, 2022, at 8 a.m. ET. Investors can participate by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will also be available on the company’s website. Intellia focuses on developing genome editing therapies through CRISPR technology, aiming to address various diseases with its in vivo and ex vivo programs.
Intellia Therapeutics (NASDAQ:NTLA) announced upcoming presentations at two investor conferences in October 2022. The Chardan’s 6th Annual Genetic Medicines Conference is scheduled for October 3, 2022, at 8:30 a.m. ET in a fireside chat format. The 2022 Truist Securities Genetic Medicine Summit will include a genome editing panel on October 20, 2022, at 9:00 a.m. ET. A live webcast of the Chardan presentation will be available on Intellia's website, with a replay accessible for 30 days.
Intellia Therapeutics announced promising interim results from the Phase 1 study of NTLA-2001, a CRISPR/Cas9 therapy for transthyretin (ATTR) amyloidosis. At doses of 0.7 mg/kg and 1.0 mg/kg, mean serum transthyretin (TTR) reductions of 93% and 92% were observed at day 28. The treatment was well-tolerated, with transitory infusion reactions as the only adverse events. These outcomes suggest NTLA-2001 may provide a single-dose treatment option for patients with cardiomyopathy manifestations of ATTR amyloidosis. Further discussions on this data are scheduled for an investor event today.